Dermata Therapeutics, Inc. DRMA
mean Dermata Therapeutics, Inc. unless stated otherwise or the context otherwise indicates.
to the development and commercialization of products that address common and underserved skin conditions. Dermata initially was founded
with a focus on researching and developing prescription products subject to the FDA approval process. As part of this focus, we had one
lead asset, referred to as XYNGARI, also known as DMT310, which we had been studying in clinical trials for the treatment of moderate-to-severe
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M | $1.6M | — |
| SG&A | $4.8M | $4.3M | $4.0M | $4.0M | $4.4M | $1.6M | — |
| Total operating expenses | $7.8M | $12.5M | $8.0M | $9.7M | — | — | — |
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M | -$3.2M | — |
| Interest expense | — | — | — | $63.6K | $45.6K | $197.3K | — |
| Pre-tax income | — | -$12.3M | -$7.8M | -$9.6M | -$7.9M | -$3.2M | — |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M | -$3.2M | — |
| EPS, basic | -8.16 | -80.32 | -39.99 | -13.92 | -2.43 | -1.69 | — |
| EPS, diluted | -8.16 | -80.32 | -39.99 | — | — | — | — |
| Shares, diluted (wtd. avg.) | $926.2K | $153.0K | $194.9K | — | $4.3M | $1.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.5M | $3.2M | $7.4M | $6.2M | $10.8M | $530.4K | — |
| Total current assets | — | — | — | — | $11.6M | $605.5K | — |
| Property, plant and equipment | — | — | — | — | $0 | $0 | — |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M | $605.5K | — |
| Accounts payable | $460.8K | $808.0K | $866.0K | $496.7K | $515.2K | $104.3K | — |
| Short-term debt | — | — | — | — | $0 | $556.2K | — |
| Total current liabilities | — | — | — | — | $1.5M | $3.8M | — |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922.6K | $1.5M | $3.8M | — |
| Retained earnings | -$73.2M | -$65.7M | -$53.4M | -$45.6M | -$36.0M | -$28.1M | — |
| Total equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M | -$3.2M | -$210.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M | -$4.0M | — |
| Stock-based compensation | $143.7K | $657.6K | $522.1K | $930.3K | $1.9M | $0 | — |
| Financing cash flow | $12.1M | $6.9M | $7.6M | $4.3M | $16.0M | $2.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012992.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |